Objective To investigate the effects of different magnitudes of mechanical strain on proliferation and alkaline phosphatase (ALP) activity in mouse osteoblast-like cells (MC3T3-E1). Methods MC3T3-E1 cells were subjected to 0%, 6%, 12%, 18% elongation for 24h and 48h by using multi-passage cell stress loading system respectively. MTT colorimetric method was used to assess the proliferation of the cell, ALP activity was detected by ALP assay kit. Results The proliferation of MC3T3-E1 cells was increased significantly 24h and 48h after mechanical strain treatment concomitant with increasing stretching force (P

Drugs, Chinese Herbal ; therapeutic use ; Humans ; Indoles ; therapeutic use ; Liver Neoplasms ; drug therapy ; Male ; Middle Aged ; Pyrroles ; therapeutic use

OBJECTIVETo observe the effect of Modified Yiqi Chutan Recipe (MYCR) on blood flow perfusion in treating mid-late stage non-small cell lung cancer (NSCLC) patients by using multislice CT perfusion (CTP) , and to assess the relationship between each CTP parameter and the prognosis as well.

METHODSTotally 87 mid-late stage NSCLC patients were randomly assigned to the treatment group (44 cases, Shenyi Capsule + MYCR +chemotherapy) and the control group (43 cases, chemotherapy alone) in the ratio of 1:1. And 21 days consisted of 1 therapeutic course, 4 courses in total. All of them underwent CTP of primary tumor and routine thoracic CT examination (plain CT and enhancement CT) 3 times (before therapy, after 2 and 4 cycles). CT findings were analyzed for tumor size and perfusion parameters [blood flow (BF), blood volume (BV), permeability surface (PS), mean transit time (MTT), and time to peak (TP) before and after treatment, and relationship between perfusion parameters and prognosis was also assessed.

RESULTSIn 87 cases, 7 dropped out and 80 cases were available, 40 in the treatment group and 40 in the control group. (1) The relief rate was 47.5% (19/40) and the total stable rate was 77.5% (31/40) in the treatment group, and they were 40.0% (16/40) and 65.0% (26/40) in the control group, with no statistical difference between the two groups (χ² = 0.672, 1.227; P > 0.05). (2) Compared with before treatment group in the same group, BF and PS decreased, and MTT increased in the two groups after 2 and 4 courses (P < 0.05); BE and PS decreased, and MTT increased in the control group after 2 courses (P < 0.05). Compared with the control group after 4 courses, BE decreased more significantly in the treatment group (P < 0.05). (3) After 4 courses, all patients were assigned to the remission group (35 cases) and the non-remission group (45 cases) according to the RECIST standard. Compared with before treatment in the same group, BF, BF, and PS all decreased, and MTT increased in the remission group after treatment (all P < 0.05); BF increased in the non-remission group after treatment (P < 0.05). (4) All patients were assigned to the BE increase group (34 cases) and the BE decrease group (46 cases) according to changed BE values after treatment. Results showed the mean survival rate was 246 days in the BF increase group (the 1-year accumulative survival rate being 13.0%) and 387 days in the BE decrease group (the 1-year accumulative survival rate being 53.1%). The life span was prolonged and the 1-year accumulative survival rate was elevated in the BE increase group, with statistical difference as compared with the BE decrease group (χ² = 19.057, P < 0.01).

CONCLUSIONSShenyi Capsule plus MYCR could reduce BE in mid-late stage NSCLC patients , improve vascular permeability, showing better synergistic effect with chemotherapy. CTP could not only reflect the change of tumor size, but also reflect vascular function of the tumor. Meanwhile, changes of CTP parameters were closely associated with prognosis. Patients with post-treatment decreased BE value had better prognosis and longer life span.

Capillary Permeability ; drug effects ; Carcinoma, Non-Small-Cell Lung ; diagnosis ; drug therapy ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Phytotherapy ; Tomography, X-Ray Computed

Objective:To investigate the effects of different shapes of implant on stress distribution in implant-bone interface and to select the most appropriate shape for orthodontic anchorage. Method:3-dimesional finite element analysis method was used to analyze the stress and strain in implant-bone interface of knife-edged threaded, square threaded and smooth type implants.Results: The first,second and third main stress (MPa) of knife-edged threaded implant were 6.67, 1.47 and 0.52 respectively with 7.72 MPa of Von Mises stress;those of square threaded 13.00,2.51,0.57 and 11.8;smooth type 10.50,2.50,0.67 and 12.60,respectively. The variables of alveolar bone at the cervix of knife-edged threaded,square threaded and smooth type implants were (0.11×10-3), （0.13×10-3） and （0.94×10-4) mm respectively. Conclusion: The stress in knife-edged threaded implant-bone interface and alveolar bone deformation at the cervix of the implants is minimal,therefore the implants are more suitable for orthodontic anchorage.

Objective:To establish a 3-dimensional finite element model for implant in molar deprived region of mandible. And to lay basis for precise analysis for the biomechanic characteristics of implant anchorage system. Methods:The cross section outline drawn from the molar deprived region of mandible was input into a computer, and ANSYS 5.5 (Swanson Analysis Systems, Inc. Houston, USA) finite element analysis software was used to perform the finite element modeling of the mandible.Results:The cross section outline of the mandible,imitated by a spline curve was smooth and lifelike. This cross section outline was extruded into a three dimensional model. The three dimensional models of the implant and mandible could be smartly meshed to obtain the finite element model of mechanics. Conclusion: An effective 3-dimensional finite element biomechanical analysis model for implant as orthodontic anchorage was established.

The study included 24 patients of lung cancer with bone metastasis, 26 patients of lung cancer without bone metastasis and 27 healthy controls. The serum levels of β-crosslaps of type Ⅰ collagen (β-CTX), M-MID and urinary β-CTX/creatinine (CTX/CR) were measured by ELISA. Results showed that the serum levels of β-CTX and urinary CTX/CR in lung cancer patients with bone metastasis were significantly higher than those without bone metastasis (P ＜ 0. 01 ). The findings suggest that the measurement of serum β-CTX and urinary CTX/CR may indicate bone metastasis in lung cancer.

0.05). At stage 2 to 3, the changes of point A was the greatest. Conclusion: Timing of headgear treatment based on the morphological variation of cervical vertebra can obtain the maximum desirable orthopedic effect.

Objective To evaluate the clinical effects,CT features and side-effects of percutaneous microwave coagulation therapy(PMCT) in the treatment of peripheral lung cancer.Methods CT-guided PMCT was applied to 16 cases of peripheral lung cancer from August 2003 to October 2004 in this hospital.Pathological or cytological findings showed 9 cases of squamous carcinoma and 7 cases of adenocarcinoma.A needle microwave antenna was applied into the tumor percutaneously under CT guidance.In each emission of microwave,the tumor was ablated with a 2 450 Hz microwave coagulation output of 65~75 W for 3~5 min.According to the size and shape of the tumor,single or multiple ablation emission was selected.Results The operation time was(15~60) min(mean,35 min).Complete remission(CR) was achieved in 1 case,partial remission(PR) in 4 cases,and no changes(NC) in 11.Follow-up observations in the 16 cases for 3~15 months(mean,9.5 months) found 2 cases of tumor metastasis and 1 case of death.Conclusions Percutaneous microwave coagulation therapy is a safe,micro-invasive,and effective treatment for the management of peripheral lung cancer.

Objective To investigate the clinical presentation, hormonal profile and metabolic abnormalities in subgroups of women with PCOS and explore a reasonable classification for PCOS. Methods A cross-sectional study of 192 women with PCOS (14-38 years of age) was performed. The patients were divided into 3 groups of A, B and C according to the revised 2003 consensus on diagnostic criteria and also divided into 2 groups according to body mass index(BMI) : group A(n=110), long term anovulation, clinical and biochemical evidence of high androgen level, ovary enlargement with its size larger than 10 ml or number of small follicles of 2-9 mm ≥12 under ultrasound with exclusion of other diseases caused by high androgen;group B(n=46), long term anovulation, clinical and biochemical evidence of high androgen level;group C(n=36), long term anovulation, ovary enlargement with its size larger than 10 ml or number of small follicles of 2-9 mm ≥12 under ultrasound with exclusion of other disease caused by high androgen; obesity PCOS group (OB-PCOS,n=70),BMI≥25(kg/m~2); no obesity PCOS group (NOB-PCOS,n=122), BMI

Objective To evaluate retroperitoneal laparoscopic adrenalectomy. Methods From June of 1999 to January of 2001, retroperitoneal laparoscopic adrenalectomy was performed on 52 patients with adrenal diseases, including 34 cases of aldosterone-preducing adenoma,3 nodular hyperplasia bilateral in 1, 5 Cushing's syndrom,1 Cushing's disease, 3 adrenal pheochromacytoma (bila- teral in 1), 4 nonfunctional adrenal adenoma, 1 myelolipoma and 1 metastasis carcinoma. Results 54 sessions of retroperitoneal adrenalectomy have been carried out for 52 patients (2 on both sides) with success in 51 procedures. The procedure was converted to open operation in 3 occasions because of bleeding or adhesion. The mean operation time was 135 minutes (40～270 min), and the estimated blood loss 45 ml (5～150 ml) with no need of transfusion. The postoperative hospital stay was 6 d (3～14 d) and the mean analgesia consumed 8.5 mg (0～50 mg) of morphine equivalents with no need of any analgesic at all in 17 patients. Conclusions Retroperitoneal laparoscopic adrenalectomy was less traumatic to the patients, with less postoperative discomfort and quicker recovery. The procedure should be considered as the first choice of therapy for benign adrenal diseases.